Vanadium(V) complexes of a tripodal ligand, their characterisation and biological implications.

The reaction of the tripodal tetradentate dibasic ligand 6,6'-(2-(pyridin-2-yl)ethylazanediyl)bis(methylene)bis(2,4-di-tert-butylphenol), H2L(1)I, with [V(IV)O(acac)2] in CH3CN gives the V(V)O-complex, [V(V)O(acac)(L(1))] 1. Crystallisation of 1 in CH3CN at ∼0 °C gives dark blue crystals of 1, while at room temperature it affords dark green crystals of [{V(V)O(L(1))}2µ-O] 3. Upon prolonged treatment of 1 in MeOH, [V(V)O(OMe)(MeOH)(L(1))] 2 is obtained. All three complexes were analysed by single-crystal X-ray diffraction, depicting a distorted octahedral geometry around vanadium. In the reaction of H2L(1) with V(IV)OSO4 partial hydrolysis of the tripodal ligand results in the elimination of the pyridyl fragment of L(1) and the formation of H[V(V)O2(L(2))] 4 containing the ONO tridentate ligand 6,6'-azanediylbis(methylene)bis(2,4-di-tert-butylphenol), H2L(2)II. Compound 4, which was not fully characterised, undergoes dimerization in acetone yielding the hydroxido-bridged [{V(V)O(L(2))}2µ-(OH)2] 5 having a distorted octahedral geometry around each vanadium. In contrast, from a solution of 4 in acetonitrile, the dinuclear compound [{V(V)O(L(2))}2µ-O] 6 is obtained, with a trigonal bipyramidal geometry around each vanadium. The methoxido complex 2 is successfully employed as a functional catechol-oxidase mimic in the oxidation of catechol to o-quinone under air. The process was confirmed to follow a Michaelis-Menten type kinetics with respect to catechol, the Vmax and KM values obtained being 7.66 × 10(-6) M min(-1) and 0.0557 M, respectively, and the turnover frequency is 0.0541 min(-1). A similar reaction with the bulkier 3,5-di-tert-butylcatechol proceeded at a much slower rate. Complex 2 was also used as a catalyst precursor for the oxidative bromination of thymol in aqueous medium. The selectivity shows quite interesting trends, namely when not using excess of the primary oxidizing agent, H2O2, the para mono-brominated product corresponds to ∼93% of the products and no dibromo derivative is formed.

Thirty years through vanadium chemistry.

The relevance of vanadium in biological systems is known for many years and vanadium-based catalysts have important industrial applications, however, till the beginning of the 80s research on vanadium chemistry and biochemistry did not receive much attention from the scientific community. The understanding of the broad bioinorganic implications resulting from the similarities between phosphate and vanadate(V) and the discovery of vanadium dependent enzymes gave rise to an enormous increase in interest in the chemistry and biological relevance of vanadium. Thereupon the last 30years corresponded to a period of enormous research effort in these fields, as well as in medicinal applications of vanadium and in the development of catalysts for use in fine-chemical synthesis, some of these inspired by enzymatic active sites. Since the 80s my group in collaboration with others made contributions, described throughout this text, namely in the understanding of the speciation of vanadium compounds in aqueous solution and in biological fluids, and to the transport of vanadium compounds in blood plasma and their uptake by cells. Several new types of vanadium compounds were also synthesized and characterized, with applications either as prospective therapeutic drugs or as homogeneous or heterogenized catalysts for the production of fine chemicals. The developments made are described also considering the international context of the evolution of the knowledge in the chemistry and bioinorganic chemistry of vanadium compounds during the last 30years. This article was compiled based on the Vanadis Award presentation at the 9th International Vanadium Symposium.